Toll Free: 1-888-928-9744

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Pipeline Review, H2 2016

Published: Dec, 2016 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Pipeline Review, H2 2016', provides in depth analysis on Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted pipeline therapeutics. 

The report provides comprehensive information on the Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: 
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14)
- The report reviews Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) Overview 6 Therapeutics Development 7 Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Products under Development by Stage of Development 7 Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Products under Development by Therapy Area 8 Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Products under Development by Indication 9 Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Products under Development by Companies 12 Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Therapeutics Assessment 14 Assessment by Monotherapy/Combination Products 14 Assessment by Mechanism of Action 15 Assessment by Route of Administration 16 Assessment by Molecule Type 17 Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Companies Involved in Therapeutics Development 19 Gilead Sciences Inc 19 MedDay SA 20 Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Drug Profiles 21 Antisense Oligonucleotide to Inhibit ACC2 for Obesity - Drug Profile 21 Product Description 21 Mechanism Of Action 21 R&D Progress 21 biotin - Drug Profile 22 Product Description 22 Mechanism Of Action 22 R&D Progress 22 ND-630 - Drug Profile 26 Product Description 26 Mechanism Of Action 26 R&D Progress 26 ND-646 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 ND-654 - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 Acetyl CoA Carboxylase 2 (ACC2 or ACC Beta or ACACB or EC 6.4.1.2 or EC 6.3.4.14) - Featured News & Press Releases 31 Sep 19, 2016: Salk Institute: Targeting fat to treat cancer 31 Sep 14, 2016: Positive Preclinical Data With MD1003 (High Dose Pharmaceutical Grade Biotin) in X-Linked Adrenoleukodystrophy to be Presented at European Committee for Treatment and Research in Multiple Sclerosis 2016 32 Sep 02, 2016: MedDay Announces Publication of MD1003 Phase IIb/III Study in the Multiple Sclerosis Journal 32 May 25, 2016: MedDay attends European Academy of Neurology 2016 and presents extension phase results of the MS-SPI trial 33 Apr 21, 2016: MedDay reports full data from pivotal Phase IIb/III MS-SPI / MS-ON studies with MD1003 in Multiple Sclerosis at AAN 34 Dec 01, 2015: MedDay provides update on MS-ON study of MD-1003 36 Oct 07, 2015: MedDay reports additional positive analyses of its pivotal study with MD1003 in patients with primary and secondary Progressive Multiple Sclerosis 38 Aug 06, 2015: Medical Need Europe appoints Durbin as latest distribution partner 39 Jun 19, 2015: MedDay reports additional positive data of its pivotal Phase III study with MD1003 in patients with Progressive Multiple Sclerosis 39 Jun 17, 2015: MedDay and DSM announce a partnership to produce pharmaceutical grade D-Biotin to treat progressive multiple sclerosis 41 Apr 24, 2015: MedDay reports positive pivotal Phase III study results with MD1003 in patients with Progressive Multiple Sclerosis 41 Apr 21, 2015: Nimbus Therapeutics Announces Initiation of Clinical Studies for ACC Inhibitor 42 Apr 17, 2015: MedDay announces its pivotal Phase III study of MD1003 in patients with Progressive Multiple Sclerosis meets primary endpoint 43 Apr 07, 2015: MedDay provides update on pioneering pivotal Phase III study design in Progressive Multiple Sclerosis 44 Mar 04, 2015: MedDay to present Pivotal Phase III data in Progressive Multiple Sclerosis at AAN Annual Meeting 45 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development for, H2 2016 7 Number of Products under Development by Therapy Area, H2 2016 8 Number of Products under Development by Indication, H2 2016 9 Comparative Analysis by Late Stage Development, H2 2016 10 Comparative Analysis by Early Stage Products, H2 2016 11 Number of Products under Development by Companies, H2 2016 12 Products under Development by Companies, H2 2016 13 Assessment by Monotherapy/Combination Products, H2 2016 14 Number of Products by Stage and Mechanism of Action, H2 2016 15 Number of Products by Stage and Route of Administration, H2 2016 16 Number of Products by Stage and Molecule Type, H2 2016 18 Pipeline by Gilead Sciences Inc, H2 2016 19 Pipeline by MedDay SA, H2 2016 20



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify